Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial.
Howard I. Scher
Consultant or Advisory Role - Millennium
Karim Fizazi
Consultant or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Dendreon; Ipsen; Janssen; Medivation; Millennium; Novartis; Sanofi
Connie Lee
Employment or Leadership Position - Takeda
David Maclean
Employment or Leadership Position - Takeda
Bindu Tejura
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Iain James Webb
Employment or Leadership Position - Takeda
Niels Geert Borgstein
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Robert Dreicer
Consultant or Advisory Role - Dendreon; Endo Pharmaceuticals; Janssen; Medivation; Millennium
Honoraria - Dendreon; Janssen
Research Funding - BIND Biosciences; Endo Pharmaceuticals; Millennium; Progenics